Chugai Pharmaceutical Co Ltd
DUS:CUP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Chugai Pharmaceutical Co Ltd
DUS:CUP
|
JP |
|
H
|
Hosiden Corp
F:HOD
|
JP |
|
Irving Resources Inc
OTC:IRVRF
|
CA |
|
Macromill Inc
F:MA5
|
JP |
|
G
|
GS Chain PLC
OTC:GSCHF
|
UK |
|
ShaMaran Petroleum Ltd
OTC:SHPLF
|
BM |
|
NH Foods Ltd
OTC:NIPMY
|
JP |
|
American West Metals Ltd
F:R84
|
AU |
|
D
|
Daishin Securities Co Ltd
KRX:003547
|
KR |
|
R
|
Riber SA
F:RI7
|
FR |
|
J
|
Jost Werke SE
DUS:JST
|
DE |
|
Encavis AG
F:ECV
|
DE |
|
Lenzoloto PAO
MOEX:LNZLP
|
RU |
|
Western Gold Exploration Ltd
OTC:WGELF
|
CA |
|
Mader Group Ltd
OTC:MADGF
|
AU |
|
O
|
Otsuka Corp
F:OTK
|
JP |
|
T
|
Troilus Gold Corp
F:CM5R
|
CA |
|
C
|
Cal-Comp Electronics Thailand PCL
SET:CCET
|
TH |
Chugai Pharmaceutical Co Ltd
Chugai Pharmaceutical is a Japanese drug company that discovers, develops, manufactures, and sells prescription medicines. Its main products are treatments for cancer, immune diseases, blood disorders, bone and joint conditions, and other serious illnesses. The company is focused on medicines that doctors prescribe and hospitals use, not consumer health products. Chugai makes money mainly by selling its own branded drugs to hospitals, clinics, pharmacies, and distributors. It also earns income through research partnerships and licensing arrangements, especially with Roche, its long-time global partner. That relationship helps Chugai move products from research into wider markets while keeping a strong base in Japan. What makes Chugai’s business model different is its focus on high-value specialty medicines and on scientific research rather than large-volume generic drugs. Its role in the healthcare chain is to turn lab research into regulated therapies that doctors can prescribe for hard-to-treat diseases. This makes the company depend on innovation, patents, and long product lifecycles rather than simple manufacturing scale.
Chugai Pharmaceutical is a Japanese drug company that discovers, develops, manufactures, and sells prescription medicines. Its main products are treatments for cancer, immune diseases, blood disorders, bone and joint conditions, and other serious illnesses. The company is focused on medicines that doctors prescribe and hospitals use, not consumer health products.
Chugai makes money mainly by selling its own branded drugs to hospitals, clinics, pharmacies, and distributors. It also earns income through research partnerships and licensing arrangements, especially with Roche, its long-time global partner. That relationship helps Chugai move products from research into wider markets while keeping a strong base in Japan.
What makes Chugai’s business model different is its focus on high-value specialty medicines and on scientific research rather than large-volume generic drugs. Its role in the healthcare chain is to turn lab research into regulated therapies that doctors can prescribe for hard-to-treat diseases. This makes the company depend on innovation, patents, and long product lifecycles rather than simple manufacturing scale.
Revenue: Chugai reported first-half revenue of JPY 663.3 billion, up 14.7% year on year, and said it is on track to meet its full-year forecast.
Profit: Core operating profit rose 21% to JPY 329.1 billion, helped by higher sales, a stronger mix in overseas products, and more royalty and one-time income.
Pipeline: The company filed 8 regulatory applications in Japan, started 2 Phase III studies for NXT007, and highlighted AQUA07 and PiaSky as important development milestones.
Growth drivers: Nemluvio and Foundayo were cited as key new products supporting medium-term growth, with Nemluvio’s global sales reaching USD 433 million in the first half.
Capital use: Management created a strategic investment department to pursue more active M&A, in-licensing, and technology investments, backed by a strong cash position.
Shareholder returns: The company kept its dividend policy intact and expects an annual dividend of JPY 132 per share, marking a 10th straight year of ordinary dividend growth.
Management
Dr. Osamu Okuda is a prominent figure in the pharmaceutical industry, currently serving as the President and CEO of Chugai Pharmaceutical Co., Ltd., a leading research-based pharmaceutical company in Japan. Dr. Okuda joined Chugai in 1992, and over the years, he has held numerous key positions within the company, gaining extensive experience in both domestic and international markets. He graduated from the University of Tokyo’s Faculty of Economics, providing him with a strong foundation in business and economic strategies. Dr. Okuda played a pivotal role in various divisions, including marketing, strategic planning, and lifecycle management, significantly contributing to Chugai's growth and innovation. Under his leadership, Chugai has focused on advancing research and development, leveraging biopharmaceutical technologies, and emphasizing personalized healthcare solutions. Dr. Okuda is known for his commitment to enhancing Chugai’s global presence and fostering collaboration within the healthcare sector to address unmet medical needs. His leadership reflects a balance of strategic vision and commitment to scientific excellence, ensuring that Chugai continues to deliver innovative therapies that improve patient outcomes worldwide.
He graduated from the University of Tokyo’s Faculty of Economics, providing him with a strong foundation in business and economic strategies. Dr. Okuda played a pivotal role in various divisions, including marketing, strategic planning, and lifecycle management, significantly contributing to Chugai's growth and innovation.
Under his leadership, Chugai has focused on advancing research and development, leveraging biopharmaceutical technologies, and emphasizing personalized healthcare solutions. Dr. Okuda is known for his commitment to enhancing Chugai’s global presence and fostering collaboration within the healthcare sector to address unmet medical needs.
His leadership reflects a balance of strategic vision and commitment to scientific excellence, ensuring that Chugai continues to deliver innovative therapies that improve patient outcomes worldwide.
I apologize, but I couldn't find any information about an individual named Mr. Iwaaki Taniguchi associated with Chugai Pharmaceutical Co., Ltd. It's possible he might not be a publicly recognized figure or executive officer within the company. If there is anything else you would like to know or ask about, feel free to let me know!
Toshiya Sasai is an executive at Chugai Pharmaceutical Co., Ltd., a prominent Japanese pharmaceutical company known for its innovative research and development activities in biologics and other pharmaceutical fields. As a leader within the company, Sasai has contributed to the advancement of Chugai's strategic initiatives and operational goals. Chugai Pharmaceutical is highly regarded for its focus on oncology, renal diseases, and bone and joint diseases, and executives like Sasai play a crucial role in navigating the company through the complex landscape of pharmaceutical research and market demands. Details about his specific role or achievements may vary, as company executive positions and responsibilities can change over time.
Masayoshi Higuchi is a prominent figure at Chugai Pharmaceutical Co., Ltd., a leading research-based pharmaceutical company in Japan. With a strong background in the pharmaceutical industry, Higuchi has contributed significantly to the company's strategic vision and operational excellence. He has played a crucial role in enhancing Chugai's innovative capabilities and expanding its global reach. Under his leadership, the company has continued to pursue cutting-edge research and development, particularly in the field of oncology and biotechnology, strengthening its position as a pioneer in innovative therapies and personalized medicine. His expertise in business development and strategic planning has been instrumental in forging strategic alliances and partnerships with other global pharmaceutical companies, aligning with Chugai's mission to contribute to the well-being of patients worldwide through the creation of innovative medical products and services.
Junichi Takano is a notable executive in the pharmaceutical industry, serving as the Executive Vice President and Representative Director at Chugai Pharmaceutical Co., Ltd. Chugai is a Japanese company engaged in research, development, manufacturing, and marketing of pharmaceuticals. Takano has had a significant impact on the company's strategic initiatives, helping to steer its growth and innovation in drug development. His leadership has been pivotal in aligning Chugai with its mission to contribute to the medical community and human health globally by creating innovative products and services. His work focuses on enhancing the organization's operational efficiency and global presence.
Dr. Yoshiaki Ohashi is a well-regarded figure in the pharmaceutical industry, particularly known for his leadership roles at Chugai Pharmaceutical Co., Ltd., a prominent research-based pharmaceutical company in Japan. Dr. Ohashi has played a significant role in the company's efforts to advance medical treatments through innovative research and development. At Chugai Pharmaceutical, Dr. Ohashi has held various executive positions, contributing to the company's strategic direction and operational success. His expertise in the field is underpinned by a strong academic background and extensive experience in pharmaceutical research and development. Dr. Ohashi's work is focused on leveraging cutting-edge science to develop new therapies, particularly in areas with high unmet medical needs. Under his leadership, Chugai has made significant strides in oncology, immunology, and other therapeutic areas, often collaborating with international partners to enhance its research capabilities. Dr. Ohashi is known for his commitment to scientific excellence and patient-focused innovation, which aligns with Chugai's mission to contribute to the health and well-being of people around the world through the provision of innovative medical solutions. His contributions have been instrumental in solidifying Chugai's reputation as a leader in the global pharmaceutical industry.
At Chugai Pharmaceutical, Dr. Ohashi has held various executive positions, contributing to the company's strategic direction and operational success. His expertise in the field is underpinned by a strong academic background and extensive experience in pharmaceutical research and development. Dr. Ohashi's work is focused on leveraging cutting-edge science to develop new therapies, particularly in areas with high unmet medical needs.
Under his leadership, Chugai has made significant strides in oncology, immunology, and other therapeutic areas, often collaborating with international partners to enhance its research capabilities. Dr. Ohashi is known for his commitment to scientific excellence and patient-focused innovation, which aligns with Chugai's mission to contribute to the health and well-being of people around the world through the provision of innovative medical solutions. His contributions have been instrumental in solidifying Chugai's reputation as a leader in the global pharmaceutical industry.
Tetsuya Yamaguchi is a notable executive at Chugai Pharmaceutical Co., Ltd., a leading research-based pharmaceutical company in Japan. He serves as the Executive Vice President and CFO, contributing significantly to the company's financial strategies and operations. With his extensive experience in pharmaceutical finance and management, Yamaguchi plays a critical role in strategic planning, resource allocation, and financial oversight, ensuring the company's financial health and supporting its mission to innovate advanced medical solutions. His leadership and expertise help drive Chugai's growth and maintain its competitive edge in the pharmaceutical industry.
Yoshiyuki Yano is a notable figure in the pharmaceutical industry, specifically known for his executive role at Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical is a leading research-based pharmaceutical company in Japan and part of the Roche Group. Although detailed personal information about Mr. Yano might not be readily available, he is recognized for contributing to the company's strategic growth and development. In his executive capacity, Mr. Yano likely played a critical role in steering Chugai's operations, leveraging his expertise to advance the company's market position. His efforts would typically involve overseeing various departments, ensuring compliance with international pharmaceutical standards, and fostering innovative research and development initiatives. Under his leadership, Chugai Pharmaceutical has continued to focus on pioneering medicines, particularly in oncology, aiming to provide solutions that address unmet medical needs and enhance patient outcomes. As part of the company's executive team, Mr. Yano's work would be integral to maintaining Chugai's reputation as a leader in biopharmaceuticals. It's essential to refer to Chugai Pharmaceutical’s press releases or official reports for specific and updated information regarding Mr. Yoshiyuki Yano’s contributions and current role within the company.
In his executive capacity, Mr. Yano likely played a critical role in steering Chugai's operations, leveraging his expertise to advance the company's market position. His efforts would typically involve overseeing various departments, ensuring compliance with international pharmaceutical standards, and fostering innovative research and development initiatives.
Under his leadership, Chugai Pharmaceutical has continued to focus on pioneering medicines, particularly in oncology, aiming to provide solutions that address unmet medical needs and enhance patient outcomes. As part of the company's executive team, Mr. Yano's work would be integral to maintaining Chugai's reputation as a leader in biopharmaceuticals.
It's essential to refer to Chugai Pharmaceutical’s press releases or official reports for specific and updated information regarding Mr. Yoshiyuki Yano’s contributions and current role within the company.